Monoclonal antibodies (mAb) are not only useful reagents but also represent a promising type of therapeutics due to their high affinity and exquisite specificity for their antigens. A critical step in mAb generation is to identify antigen-specific antibodies. Although enzyme-linked immunosorbent assay (ELISA) has been broadly applied for antibody selection against secreted antigens, an inherent disadvantage for ELISA is the difficulty in identifying antibodies that recognize the native conformation of cell surface antigens. To overcome this drawback, the authors have developed a high-throughput cell-based antibody binding assay using fluorometric microvolume assay technology (FMAT). This method offers a homogeneous assay for detection of antibody binding to its antigen on the cell surface. To distinguish antibodies that bind to antigen on the cell surface from those that bind nonspecifically to cells, the binding is assessed using both antigen-expressing cells and related cells devoid of the antigen expression. This assay can detect antibodies at a concentration as low as 5 ng/mL and cell surface antigen as low as 9000 copies per cell. Results demonstrate that the FMAT method provides a sensitive and homogeneous assay to detect antibody binding to cell surface antigens and is amenable for high-throughput hybridoma selection. (Journal of Biomolecular Screening 2008:210-217) 
INTRODUCTION
M ONOCLONAL ANTIBODIES (MAB) AGAINST A WIDE RANGE of protein targets have been either approved or are currently under development for therapeutics. [1] [2] [3] Since hybridoma technology was established 30 years ago to generate mAb in mice, 4 murine mAb have been primarily used as research tools, rather than therapeutics, due to their immunogenicity in humans, which raised concerns for safety and efficacy. Chimerization and then humanization of murine mAb have significantly reduced their immunogenicity. The process requires sophisticated genetic manipulations, which is time-consuming and can negatively affect the affinity and potency of therapeutic mAb. The development of transgenic mice carrying the majority of the human immunoglobulin loci, XenoMouse ® technology, enables the generation of fully human antibodies directly from these mice, providing advantages over murine, chimeric, and humanized antibodies. [5] [6] [7] [8] The generation of thousands of highly diverse hybridomasecreting antibodies with various affinities and concentrations presents a challenge for the rapid selection of hybridomas producing the antibodies of interest.
The conventional antibody screening assay based on antibodyantigen binding has been the enzyme-linked immunosorbent assay (ELISA). In this method, the antigen is immobilized on the surface of ELISA microplates. Antibodies bound to the antigen on the plates are detected with horseradish peroxidase (HRP)conjugated antibodies against the immunoglobulin constant region. An HRP substrate is added for the signal generation, and the absorbance measured is directly proportional to the amount of antibody binding to the antigen. This method has proven to be very useful for the identification of antibodies to secreted antigens. However, cell surface antigens provide challenges for ELISA due to the lack of soluble antigens and/or loss of conformational epitopes in soluble antigens. Typically, a purified extracellular domain, recovered as a recombinantly expressed tagged protein, is used in ELISA for cell surface antigens. However, this method can result in loss of important conformational epitopes in the antigen domain, which may be critical for the identification of neutralizing antibodies. Moreover, several important classes of drug targets span the membrane multiple times (e.g., the 7transmembrane G-protein-coupled receptors) and have multiple extracellular loops that may have cell-based conformational constraints. For this class of antigens, it is difficult to select a functional extracellular domain for ELISA. Although one can potentially use cell-based ELISA for such targets, this method often yields low signal, high background, and more variability. In addition, cells coated onto an ELISA plate can lose important conformational epitopes. Fluorescence-activated cell sorting (FACS) analysis provides advantages over ELISA for detecting antibody binding to native cell surface antigens. In this method, antibodies bind to the antigen expressed on the cell surface and are detected with a fluorescently conjugated antibody against the immunoglobulin constant region. As fluorescence-stained cells move in a fluid stream through a beam of laser light, a flow cytometer measures a cell's relative size, granularity or internal complexity, and fluorescence intensity. Although this method measures antibody binding to the native conformation of antigens on the cell surface, it requires multiple wash steps and a complicated data collection/analysis process that is not suitable for assessing thousands of hybridomas in a timely manner. Therefore, there is a clear need for a cell-based antibody binding assay that is amenable for high-throughput hybridoma selection.
Fluorometric microvolume assay technology (FMAT) 9,10 uses a fluorescence laser scanning reader and unique image analysis software, which enables a homogeneous format for cell-or beadbased assays. Colored substances, such as the media color present in hybridoma cultures, have minimal interferences in FMAT detection due to the excitation and emission wavelengths of the red laser used by the FMAT ® 8200, providing advantages for hybridoma selection. Although the FMAT assay is similar to FACS, measuring antibody binding to the native cell surface antigens using fluorescence detection, this method provides a clear advantage in throughput compared with the FACS method. In this study, we have evaluated the utility of FMAT for high-throughput detection of antibody binding to cell surface antigens. The results demonstrate that the cell-based antibody binding assay using FMAT provides high detection sensitivity and significantly improves the throughput compared with FACS. The employment of this method in hybridoma screening has significantly improved the throughput and capability of identifying antibodies, demonstrating cell surface binding and functional activities.
MATERIALS AND METHODS

Reagents
FMAT ® 8200 Cellular Detection Systems and clear-bottom black plates were purchased from Applied Biosystems (Foster City, CA). Cy5-conjugated goat antihuman (GAH) and goat antimouse (GAM) polyclonal antibodies were purchased from Jackson ImmunoResearch (West Grove, PA). A murine mAb to the human epithelial growth factor receptor (EGFR), mAb528 (GR01), was purchased from Oncogene (Carpinteria, CA). A human mAb against human EGFR (ABX-EGF) and a human mAb, IgG 2 κ, against keyhole limpet hemocyanin (PK16.3) 11, 12 were generated in-house using XenoMouse ® technology. Cell lines of A431 (epidermal carcinoma), BX-PC3 (pancreatic carcinoma), HT29 (human colorectal adenocarcinoma), PC3 (prostate cancer), SW707 (colon cancer), and NR6 (murine fibroblast) were obtained from in-house sources. Insulin-transferrin-selenium was purchased from Sigma (St. Louis, MO). A BioMek FX was purchased from Beckman, Coulter (Fullerton, CA).
Cell culture
All the cells were grown in their specific basic media plus 10% fetal bovine serum, 2 mM L-glutamine, and 100 μg/mL penicillin-streptomycin at 37 °C and 5% CO 2 . The basic medium for A431 cells was Dulbecco's modified eagle's medium (DMEM)/F12 containing 1× insulin-transferrin-selenium. The basic media for SW707 and HT29 were DMEM/F12 and McCoy's 5A, respectively. The basic media for BXPC3 and PC3 were RPMI 1640 modified. The basic medium for NR6 cells was DMEM.
Determination of antibody binding to cell surface antigens
Antigen-expressing cells and related cells devoid of antigen expression were incubated with various concentrations of primary antibody and Cy5-conjugated antispecies antibody in 384-well FMAT plates at a specified temperature. At the end of the incubation period, cell-associated fluorescence was detected using the FMAT ® 8200. Data output from the FMAT ® 8200 included the fluorescence intensity averaged among all cells (FL1) and the number of fluorescence-labeled cells (counts) in the scanning area. The total fluorescence intensity can be determined by multiplying the FL1 and the counts. Both FL1 and counts were proportional to the amount of antibody bound to cells. The specific binding was defined as the binding of antibodies to antigen-expressing cells but not to parental cells. The nonspecific binding was defined as the binding of antibodies to parental cells or the binding of isotype control antibody to antigen-expressing cells.
Hybridoma screening using FMAT
Hybridoma supernatants in 96-well plates (50 μL/well) were diluted 5-fold by the addition of 200 μL of phosphate-buffered saline (PBS). Then, 15 μL of the diluted supernatants was transferred into two 384-well FMAT plates. This process consolidated four 96-well plates of hybridoma supernatants into 2 identical 384-well plates. The NR6 cells recombinantly engineered to express antigen-A, a human type 1 transmembrane protein, or parental NR6 cells at 2 to 7 × 10 5 cells/mL were premixed with 800 ng/mL of Cy5-GAH IgG. Then, 15 μL of the mixture of Cy5-GAH IgG and NR6-antigen-A cells was added to the first 384-well plate, and 15 μL of the mixture of Cy5-GAH IgG and parental NR6 cells was added to the second identical 384-well plate. The binding reaction was carried out at room temperature for 1 to 18 h depending on the targets. The fluorescence associated with the cells was measured by the FMAT ® 8200. The data outputs of FL1 and counts were analyzed using a Microsoft Excel macro developed in-house. Positive hybridoma supernatants were defined as those that demonstrated binding to the NR6-antigen-A cells but not to the parental cells. A known mAb against antigen-A was used as a positive control during screening. If the positive control antibody was not of human origin, a Cy5-conjugated antispecies detection antibody was added separately to the control wells.
Data analysis
FL1, counts, and total fluorescence intensity were exported to an Excel file. The Excel macro, developed in-house, systematically determined the positives from the entire FL1 or count data set based on an algorithm that took into consideration 4 user-defined criteria: (1) the threshold for specific binding based on the data from antigen-expressing cells, (2) the threshold for nonspecific binding based on the data from parental cells, and (3) the difference and (4) the ratio between the data from antigen-expressing and parental cells. Histograms of the data sets showing the appropriate distribution for each parameter were generated to allow the user to select, from a dialog box, the threshold for that parameter. A positive supernatant list was generated by the macro based on either FL1 or counts. By selecting multiple parameters, users could generate a "merged" positive list of supernatants that met all the criteria set for the parameters chosen. For example, users could obtain a list of positive hybridomas that scored highest by both "counts" and "FL1." The macro's final report listed all the positive supernatants and the corresponding original data: FL1, counts, and total fluorescence intensity from the antigen-expressing and parental cells; well ID identifying both the plate and well location of the 384-well assay plate as well as the original 96-well hybridoma plate; and the corresponding FMAT images from both cell types.
RESULTS AND DISCUSSION
Development of a high-throughput cell-based antibody binding assay using FMAT
We have developed a high-throughput cell-based antibody binding assay using FMAT. This technology provides a homogeneous assay format to assess the fluorescence associated with cells. Briefly, antigen-expressing or parental cells are incubated with an antigen-specific antibody. Binding of the antibody to cells is detected with a Cy5-conjugated antispecies antibody, and the fluorescence intensity associated with the cells is measured by the FMAT ® 8200. Antigen-specific antibody binding to antigen-expressing cells results in a fluorescence signal. In contrast, the antigen-specific antibody does not bind to the parental cells and thus does not result in a fluorescence signal. Nonspecific binding is defined as an antibody binding to the parental cells.
To determine the antibody binding specificity in a cell-based antibody binding assay, we incubated A431 cells, which express EGFR at 1.2 × 10 6 receptors/cell, 12 overnight at 4 °C with 1 μg/mL of ABX-EGF or PK16.3. SW707 cells, which express no detectable EGFR, were also incubated overnight at 4 °C with 1 μg/mL of ABX-EGF or PK16.3. The antibody binding on the cells was detected with 500 ng/mL of Cy5-GAH IgG. The FMAT images demonstrated strong binding of ABX-EGF on A431 cells (Fig. 1A) . The bright spots represented the fluorescence-stained cells. No significant binding was observed on SW707 cells by ABX-EGF ( Fig. 1B) or on A431 cells by PK16.3 (Fig. 1C) . These results suggested that ABX-EGF binding to A431 cells was highly specific to EGFR.
FIG. 1.
Binding specificity and images generated by the FMAT ® 8200. A431 cells, which express epidermal growth factor receptor (EGFR), and SW707 cells, which do not express EGFR, were stained at 4 °C overnight with 1 μg/mL ABX-EGF or isotype control (PK16.3). Antibody binding was detected with 500 ng/mL Cy5-GAH IgG. The fluorescence intensity associated with cells was measured by the FMAT ® 8200. Images represented a portion of the scanned field. The bright spots were cells that were stained by antibodies. (A) A431 cells stained by ABX-EGF, (B) SW707 cells stained by ABX-EGF, and (C) A431 cells stained by PK16.3.
Detection sensitivity of the cell-based antibody binding assay
To assess the detection limit for antibodies in the cell-based antibody binding assay, we incubated A431 cells overnight at 37 °C with titrating amounts of a murine anti-EGFR mAb, GR01, and 400 ng/mL Cy5-GAM IgG. The antibody binding to cells was measured by the FMAT ® 8200 and reported as the total fluorescence intensity ( Fig. 2A) . The binding was detectable at 5 ng/mL of GR01. The affinity for GR01 was reported to be approximately 8 nM. 13 The results demonstrated that the assay was sufficient for detecting 5-ng/mL of antibodies with low nM affinity in hybridoma supernatants. For lower affinity antibodies, the detection limit was expected to be higher than 5 ng/mL. The FMAT assay may provide advantages for detecting low-affinity antibodies due to the homogeneous format compared with assays requiring washing steps.
The fluorescence intensity was directly proportional to the concentration of GR01, up to approximately 100 ng/mL ( Fig.  2A-C) . However, the fluorescence intensity decreased as the concentrations of GR01 increased beyond 100 ng/mL ( Fig.  2A,D) . The observed hook effect was due to the homogeneous assay format. Excess unbound GR01 in the solution competed with those bound to cells for the Cy5-GAM IgG detection antibody, leading to lower fluorescence intensity on the cells (Fig.  3) . Although the hook effect was an inherent disadvantage for homogeneous assays, the detectable range for the FMAT assay was over 3 logs ( Fig. 2A) , which was sufficient for detecting antibodies in hybridoma supernatants. To minimize the hook effect, samples can be analyzed with several dilutions and/or with higher concentrations of detection antibodies.
Excessive detection antibody results in excessive background, as demonstrated in Figure 4 . A431 cells were incubated overnight at 37 °C with 1 μg/mL GR01 and titrating amounts of Cy5-GAM IgG. The total fluorescence intensity was determined by the FMAT ® 8200. In the absence of Cy5-GAM IgG, no fluorescence signal was detected. As expected, the signal increased as the concentrations of Cy5-GAM IgG increased ( Fig. 4A-C) . However, at 4 μg/mL of Cy5-GAM IgG, the background fluorescence was high and the contrast of the images was poor, diminishing the signal/noise ratio (Fig.  4D) . The optimal concentration of detection antibodies was selected empirically for each antibody. Factors that can affect the quality of the detection antibodies are fluorophore intensity, fluorophore conjugation per antibody molecule, and specificity and affinity of the antibody.
The level of cell surface antigen expression plays a pivotal role in the robustness of the assay. To determine the receptor density requirement for the assay, we assessed the binding of ABX-EGF to 5 cell lines that express various levels of EGFR in the cellbased antibody binding assay. The receptor numbers expressed on these cell lines, which had been determined by radioligand binding and FACS analysis, ranged from 0 to 1.2 × 10 6 receptors/ cell. 12 As shown in Figure 5 , higher receptor expression generally yielded higher fluorescence signals, although the correlation was not linear. The assay detected EGFR numbers as low as 9000 receptors/cell. The detection limit of the receptor numbers will vary depending on a number of factors, such as the receptor, the cells expressing the receptor, and the affinity of the antibody used. Given such sensitivity, natural cell lines and transfected cell lines with antigen expression exceeding 9000 receptors/cell are feasible for this assay. We have also successfully used transiently transfected cells in this assay (data not shown).
Hybridoma screening using the cell-based antibody binding assay
For the cell-based antibody binding assay to be useful for hybridoma screening, the assay should tolerate hybridoma media and factors secreted by hybridomas. We have tested a list of hybridoma supernatants generated from B cells harvested from XenoMouse ® immunized with keyhole limpet hemocyanin in the cell-based antibody binding assay. No fluorescence signal was detected (data not shown), suggesting that the assay can tolerate the hybridoma supernatants well and thus is suitable for hybridoma screening.
For primary hybridoma screening, the available amount of supernatants is typically limited. It is, therefore, beneficial to miniaturize the assay to minimize the demand for hybridoma supernatants and screening reagents, especially target-expressing cells. The cell-based antibody binding assay was evaluated in a 384-well format. Due to the low assay background, the signal/ noise ratio can reach as high as 88-fold, and the Z′ factor 14 can reach 0.9, suggesting that this assay can be a very robust assay for high-throughput hybridoma screening (data not shown). We routinely used the 384-well format for hybridoma selection.
Screening of 3456 hybridoma supernatants raised against antigen-A, a type I transmembrane protein, was performed using the cell-based antibody binding assay. The positive control antibody was a human mAb against antigen-A, and the negative control was PK16.3. NR6 cells expressing antigen-A and parental cells were used for screening ( Fig. 6) . Parental cells were used for defining the nonspecific binding (data not shown). square represents the positive control antibody binding, whereas the open diamond represents the isotype control antibody binding. Positive supernatants were defined as those that bound positively to NR6-antigen-A cells without binding to parental cells (sample A). Nonspecific antibodies were defined as those bound positively to both cell types. A third class of supernatants demonstrated positive binding to both NR6-antigen-A and parental cells with significantly higher binding to NR6-antigen-A cells. An explanation for this is that the supernatant of the hybridoma culture contained more than 1 mAb, one that binds antigen-A and a second that binds to the cells nonspecifically. The antigen-Aspecific mAb can subsequently be cloned out of the mixture. The FMAT image of sample A corresponds to a positive supernatant that bound to NR6-antigen-A cells. The FMAT image of sample B corresponds to a negative supernatant that did not bind to NR6antigen-A cells. Although FACS is not suitable for primary screening of large numbers of hybridoma supernatants due to its labor-intensive assay and time-consuming data analysis, FACS has been a widely acceptable technique for characterizing antibody binding to cells. To compare the FMAT assay with FACS, we used both methods to screen 167 hybridoma supernatants in parallel. Results demonstrated that 43 supernatants were positive in the FMAT assay. Among these, 35 supernatants were positive in the FACS assay (Fig. 7) . The positive rate was slightly higher for FMAT than for FACS, probably due to the homogeneous FMAT assay format that was more sensitive in detecting lowaffinity antibodies. On the other hand, the homogeneous format may increase assay interference, leading to a higher false-positive rate. In a typical implementation of the FMAT screening process, positives would be confirmed in a secondary confirmatory screen.
Although FACS demonstrated no limitation in identifying positive supernatants when the antibody concentration was high, the FMAT assay may not be able to detect a positive supernatant if the antibody concentration is higher than the optimal detection range ( Fig. 2A) . This phenomenon could present a problem during hybridoma screening. The concentration of total IgG in hybridoma supernatants generally ranged from 0.1 to 50 μg/mL and was unknown before screening. False negatives were expected when the antibody concentration exceeded 10 μg/mL. To minimize the false negatives, we usually made a dilution of 1:10 for hybridoma supernatants during screening. At 1:10 dilution, the antibody concentrations for most of the supernatants would fall into the detectable range based on results for GR01 ( Fig. 2A) . To further minimize false negatives, hybridoma screening can be performed at 4 concentrations of supernatants. The results from parallel screening (1 vs. 4 concentrations) suggested that 5% to 10% more hits may be identified when hybridoma supernatants are screened at 4 concentrations (data not shown). Screening with multiple concentrations of supernatant, although preferable to minimize false negatives, reduced the throughput significantly. Thus, screening was routinely performed with a single concentration of supernatants.
The availability of cell lines expressing medium to high levels of the antigen and antibodies with high affinity and specificity for the antigen are key factors for a robust assay. The FMAT technology is generally compatible with most cell types tested, both suspension and adherent cells, and thus not limiting to any antigen-expressing cells for this assay. Individual isolated cells are critical for accurate FMAT measurement, presenting challenges for cells that tend to clump.
In addition, cells can be frozen in aliquots and thawed immediately prior to use with no significant loss of signal and with little compromise to background. The majority of our stably transfected cell lines showed no significant loss of signal up to 1 year after storage. Although this method required some extra developmental setup initially, the savings in time and effort to scale up cells for a large screen and the reliability of having a large number of cells on a day's notice were well worth the initial effort.
The results demonstrate that the cell-based antibody binding assay using FMAT is a sensitive high-throughput assay for hybridoma screening. Integration of this assay into the hybridoma screening process dramatically enhanced the throughput for cell-based hybridoma screening. More importantly, cell-based hybridoma screening improved the identification of mAb that bind to cell surface antigens and exhibit functionally neutralizing properties. For example, FMAT screening identified potently neutralizing mAb with epitopes that were missed in ELISA-based screens against purified recombinant extracellular domains. Furthermore, potently functional mAb against cell surface antigens with multispanning regions such as G-protein-coupled receptors were identified using the cell-based antibody binding assay.
MAb have tremendous utility as therapeutics for human diseases. Cell surface proteins are a valuable class of target for mAb therapeutics because they play pivotal roles in cell functions and are readily accessible by mAb. In addition, mAb against cell surface proteins can elicit effector-based cell-killing functions, thus providing a useful class of targets for toxin-conjugated antibodies. Considering the potential complexity of protein conformation on cell surfaces, part of the challenge in generating mAb against cell surface proteins is the identification of antibodies that recognize the native antigen conformation. The addition of a robust FMAT-based high-throughput cell-based assay in the hybridoma screening process significantly improved the discovery of functional antibodies against cell surface proteins.
